Fundraising Fox

Biotech Late Stage Investors & VC Firms

652 firms in this list, with a median first check of $1M. 131 of them lead rounds. Generated from verified public data and updated continuously.

VantagePoint Capital Partners
Silicon ValleySeed–Late Stage$2M – $100M
19 people
Calculus Capital Ltd.
LondonSeed–Late Stage$2.5M
31 people
Sanofi Ventures
CambridgeSeed–Late Stage$5M
14 people
Innovation Industries
AmsterdamSeed–Late Stage$2.2M – $54M
25 people
Ysios Capital
BarcelonaSeries A–Late Stage$5.4M – $21.6M
25 people
Odyssey Investment Partners
New YorkGrowth–Late Stage$100M – $300M
24 people
GroveStreet
NewtonSeries A–Late Stage
41 people
ARCHIMED Japan
LyonGrowth–Late Stage$10.8M – $1.1B
22 people
Rho Ventures
New YorkPre-Seed–Late Stage$2M – $15M
10 people
Fortune Venture Capital
ShenzhenSeed–Late Stage$425K – $73M
11 people
UKSE
SheffieldSeries A–Late Stage$31.8K – $1.3M
38 people
Novartis Venture Fund
BaselPre-Seed–Late Stage$5M – $25M
22 people
Claret Capital Partners
LondonSeries A–Late Stage
30 people
JDRF T1D Fund
BostonSeed–Late Stage
30 people
McWin Capital Partners
LondonSeries B–Late Stage
32 people
K2 HealthVentures
BostonSeries A–Late Stage$10M – $100M
27 people
OMERS Private Equity Inc.
TorontoGrowth–Late Stage
26 people
iSelect Fund
St. LouisSeed–Late Stage$250K – $2M
10 people
Movac
AucklandSeed–Late Stage$600K – $3M
27 people
Safar Partners
CambridgePre-Seed–Late Stage
17 people
Lumira Ventures
TorontoPre-Seed–Late Stage$1M – $10M
18 people
EcoR1 Capital
San FranciscoSeed–Late Stage
17 people
Bootstrap Europe
LondonSeries A–Late Stage
24 people
Impact Fund Denmark
CopenhagenSeed–Late Stage$2.2M – $70.2M
36 people

Related lists

Data sourced from public filings and firms' own websites — see our methodology.